Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.72 +3.0%	$24.08	$12.21 ▼ $41.31	$563.02M	-0.2	507,628 shs	776,010 shs
APLS Apellis Pharmaceuticals	$26.58 +11.2%	$19.83	$16.10 ▼ $41.94	$3.02B	0.78	2.86 million shs	4.70 million shs
KYMR Kymera Therapeutics	$40.73 +2.2%	$44.86	$19.44 ▼ $53.27	$2.85B	2.18	589,298 shs	831,580 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+0.55%	-15.11%	-23.24%	+3.39%	-40.41%
APLS Apellis Pharmaceuticals	+0.21%	-1.24%	+22.94%	+43.11%	-33.90%
KYMR Kymera Therapeutics	+5.81%	-7.21%	-10.36%	+34.02%	-6.19%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	3.108 of 5 stars	4.4	0.0	0.0	0.0	3.3	2.5	0.6
APLS Apellis Pharmaceuticals	4.6689 of 5 stars	4.3	3.0	0.0	4.4	2.7	2.5	0.6
KYMR Kymera Therapeutics	3.2638 of 5 stars	4.6	3.0	0.0	0.0	1.7	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	122.61% Upside
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	28.36% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.13% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANAB, APLS, MOR, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	6.36	N/A	N/A	($1.60) per share	-12.95
APLS Apellis Pharmaceuticals	$781.37M	4.30	N/A	N/A	$1.24 per share	21.44
KYMR Kymera Therapeutics	$47.07M	61.87	N/A	N/A	$13.59 per share	3.00
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	N/A
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	N/A
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A

Latest ANAB, APLS, MOR, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
KYMR Kymera Therapeutics	N/A	8.32	8.49
MOR MorphoSys	4.98	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
APLS Apellis Pharmaceuticals	96.29%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
APLS Apellis Pharmaceuticals	6.50%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable

ANAB, APLS, MOR, and KYMR Headlines

Recent News About These Companies

MorphoSys takeover delivers phase 3 win for Novartis

August 11 at 9:49 AM | pharmaphorum.comP

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

August 11 at 9:49 AM | biopharmadive.comB

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025 | finance.yahoo.com

Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight

March 21, 2025 | theglobeandmail.com

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

February 12, 2025 | seekingalpha.com

VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

January 15, 2025 | healio.comH

Novartis closing Morphosys facilities, laying off 330 workers

January 8, 2025 | bioworld.comB

Swiss pharma giant Novartis to close biotech firm Morphosys

December 20, 2024 | swissinfo.chS

Novartis to shut MorphSys sites amid pelabresib delay

December 20, 2024 | thepharmaletter.comT

Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

December 19, 2024 | biospace.comB

Novartis sheds MorphoSys staff, sites after pelabresib delay

December 19, 2024 | pharmaphorum.comP

Novartis shutters MorphoSys sites, lays off staff

December 19, 2024 | finance.yahoo.com

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

December 19, 2024 | reuters.com

Novartis raises mid-term sales guidance

November 21, 2024 | seekingalpha.com

Novartis: launch of Morphosys drug by could be 2027 or later

November 21, 2024 | reuters.com

Idiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).

November 14, 2024 | theglobeandmail.com

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

November 12, 2024 | manilatimes.netM

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

November 6, 2024 | biopharmadive.comB

Tango stock plunges 28% amid pipeline updates, Q3 earnings report

November 6, 2024 | msn.com

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

November 1, 2024 | biopharmadive.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANAB, APLS, MOR, and KYMR Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.72 +0.61 (+3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$21.03 +0.31 (+1.50%)

As of 07:57 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Apellis Pharmaceuticals NASDAQ:APLS

$26.58 +2.68 (+11.21%)

Closing price 04:00 PM Eastern

Extended Trading

$26.34 -0.23 (-0.88%)

As of 07:55 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$40.73 +0.86 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$40.78 +0.05 (+0.11%)

As of 04:20 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/11/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time